{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:15:39Z","timestamp":1794003339755,"version":"4.8.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172694"],"award-info":[{"award-number":["82172694"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372792"],"award-info":[{"award-number":["82372792"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Tumor-associated macrophages (TAMs) play a crucial role in fostering an immunosuppressive tumor microenvironment, promoting cancer progression, contributing to immune evasion and resistance to immunotherapy. However, the mechanisms by which TAMs exert these effects in gastric cancer (GC) remain unclear. Human TAMs were isolated from GC patients through magnetic sorting for RNA sequencing. THP-1 cell line and mice bone marrow-derived macrophages (BMDMs) induced TAMs were applied for functional assays. Two in-house tumor microarrays were utilized for validation: the Zhongshan Cohort, comprising 135 patients, and the Zhongshan Flow Cytometry (ZSFC) Cohort, which included 60 patients. In this study, we identified a significant accumulation of TREM2\n                    <jats:sup>+<\/jats:sup>\n                    TAMs in GC tissues, correlating with poor prognosis. Functional assays revealed that targeting TREM2\n                    <jats:sup>+<\/jats:sup>\n                    TAMs suppressed GC progression both in vitro and in vivo. Mechanistically, TREM2 stabilized signal transducer and activator of transcription 1 (STAT1) by preventing its ubiquitination mediated by Tripartite Motif Containing 21 (TRIM21), while simultaneously promoting STAT1 phosphorylation via spleen-associated tyrosine kinase (SYK), leading to upregulation of CCL8 and PD-L1, fostering an immunosuppressive tumor microenvironment. Furthermore, depletion of TREM2\n                    <jats:sup>+<\/jats:sup>\n                    TAMs significantly enhanced the efficacy of anti-PD-L1 immunotherapy in GC allograft models. Collectively, our findings establish TREM2\n                    <jats:sup>+<\/jats:sup>\n                    TAMs as key drivers of GC progression and immune evasion. Targeting TREM2\n                    <jats:sup>+<\/jats:sup>\n                    TAMs represents a promising therapeutic strategy to overcome resistance to anti-PD-L1 therapy and reshape the tumor immune microenvironment.\n                  <\/jats:p>","DOI":"10.1038\/s41419-025-08198-4","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T15:35:29Z","timestamp":1763480129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["TREM2 facilitates gastric cancer progression and immune evasion via inhibiting TRIM21-mediated STAT1 degradation in tumor-associated macrophages"],"prefix":"10.1038","volume":"16","author":[{"given":"Zihao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5130-1506","authenticated-orcid":false,"given":"Peiyi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leihao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenbin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-3165","authenticated-orcid":false,"given":"Jing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"8198_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41571-023-00747-0","volume":"20","author":"AP Thrift","year":"2023","unstructured":"Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023;20:338\u201349.","journal-title":"Nat Rev Clin Oncol"},{"key":"8198_CR2","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22:1081\u201392.","journal-title":"Lancet Oncol"},{"key":"8198_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020;52:17\u201335.","journal-title":"Immunity"},{"key":"8198_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41575-022-00703-w","volume":"20","author":"M Alsina","year":"2023","unstructured":"Alsina M, Arrazubi V, Diez M, Tabernero J. Current developments in gastric cancer: from molecular profiling to treatment strategy. Nat Rev Gastroenterol Hepatol. 2023;20:155\u201370.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8198_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38:1\u201310.","journal-title":"J Clin Oncol"},{"key":"8198_CR6","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1136\/gutjnl-2022-329134","volume":"72","author":"LL Cao","year":"2023","unstructured":"Cao LL, Lu H, Soutto M, Bhat N, Chen Z, Peng D, et al. Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-\u03b3 signalling. Gut. 2023;72:2038\u201350.","journal-title":"Gut"},{"key":"8198_CR7","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","volume":"79","author":"DC Hinshaw","year":"2019","unstructured":"Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79:4557\u201366.","journal-title":"Cancer Res"},{"key":"8198_CR8","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374\u2013403.","journal-title":"Cancer Cell"},{"key":"8198_CR9","doi-asserted-by":"crossref","unstructured":"Boutilier AJ, Elsawa SF. Macrophage polarization states in the tumor microenvironment. Int J Mol Sci. 2021;22.","DOI":"10.3390\/ijms22136995"},{"key":"8198_CR10","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","volume":"23","author":"A Christofides","year":"2022","unstructured":"Christofides A, Strauss L, Yeo A, Cao C, Charest A, Boussiotis VA. The complex role of tumor-infiltrating macrophages. Nat Immunol. 2022;23:1148\u201356.","journal-title":"Nat Immunol"},{"key":"8198_CR11","doi-asserted-by":"crossref","unstructured":"Wang XL, Jiang JT, Wu CP. Prognostic significance of tumor-associated macrophage infiltration in gastric cancer: a meta-analysis. Genet Mol Res. 2016;15.","DOI":"10.4238\/gmr15049040"},{"key":"8198_CR12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13046-022-02366-6","volume":"41","author":"H Piao","year":"2022","unstructured":"Piao H, Fu L, Wang Y, Liu Y, Wang Y, Meng X, et al. A positive feedback loop between gastric cancer cells and tumor-associated macrophage induces malignancy progression. J Exp Clin Cancer Res. 2022;41:174.","journal-title":"J Exp Clin Cancer Res"},{"key":"8198_CR13","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ccr.2011.02.006","volume":"19","author":"J Chen","year":"2011","unstructured":"Chen J, Yao Y, Gong C, Yu F, Su S, Chen J, et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell. 2011;19:541\u201355.","journal-title":"Cancer Cell"},{"key":"8198_CR14","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.immuni.2018.03.018","volume":"48","author":"J Li","year":"2018","unstructured":"Li J, Lee Y, Li Y, Jiang Y, Lu H, Zang W, et al. Co-inhibitory Molecule B7 Superfamily Member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8(+) T Cells. Immunity. 2018;48:773\u201386.e5.","journal-title":"Immunity"},{"key":"8198_CR15","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/hep.25777","volume":"56","author":"H Li","year":"2012","unstructured":"Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X, et al. Tim-3\/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology. 2012;56:1342\u201351.","journal-title":"Hepatology"},{"key":"8198_CR16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nm.4308","volume":"23","author":"J Gao","year":"2017","unstructured":"Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017;23:551\u20135.","journal-title":"Nat Med"},{"key":"8198_CR17","doi-asserted-by":"publisher","first-page":"8067","DOI":"10.1158\/0008-5472.CAN-09-0901","volume":"69","author":"K Wu","year":"2009","unstructured":"Wu K, Kryczek I, Chen L, Zou W, Welling TH. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1\/programmed death-1 interactions. Cancer Res. 2009;69:8067\u201375.","journal-title":"Cancer Res"},{"key":"8198_CR18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21:799\u2013820.","journal-title":"Nat Rev Drug Discov"},{"key":"8198_CR19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41582-018-0072-1","volume":"14","author":"TK Ulland","year":"2018","unstructured":"Ulland TK, Colonna M. TREM2 - a key player in microglial biology and Alzheimer disease. Nat Rev Neurol. 2018;14:667\u201375.","journal-title":"Nat Rev Neurol"},{"key":"8198_CR20","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1158\/2159-8290.CD-23-0299","volume":"13","author":"I Yofe","year":"2023","unstructured":"Yofe I, Shami T, Cohen N, Landsberger T, Sheban F, Stoler-Barak L, et al. Spatial and temporal mapping of breast cancer lung metastases identify TREM2 macrophages as regulators of the metastatic boundary. Cancer Discov. 2023;13:2610\u201331.","journal-title":"Cancer Discov"},{"key":"8198_CR21","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jhep.2023.02.032","volume":"79","author":"J Tan","year":"2023","unstructured":"Tan J, Fan W, Liu T, Zhu B, Liu Y, Wang S, et al. TREM2(+) macrophages suppress CD8(+) T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma. J Hepatol. 2023;79:126\u201340.","journal-title":"J Hepatol"},{"key":"8198_CR22","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1002\/glia.24456","volume":"71","author":"X Chen","year":"2023","unstructured":"Chen X, Zhao Y, Huang Y, Zhu K, Zeng F, Zhao J, et al. TREM2 promotes glioma progression and angiogenesis mediated by microglia\/brain macrophages. Glia. 2023;71:2679\u201395.","journal-title":"Glia"},{"key":"8198_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109844","volume":"37","author":"M Binnewies","year":"2021","unstructured":"Binnewies M, Pollack JL, Rudolph J, Dash S, Abushawish M, Lee T, et al. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. Cell Rep. 2021;37:109844.","journal-title":"Cell Rep"},{"key":"8198_CR24","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.cell.2020.06.032","volume":"182","author":"Y Katzenelenbogen","year":"2020","unstructured":"Katzenelenbogen Y, Sheban F, Yalin A, Yofe I, Svetlichnyy D, Jaitin DA, et al. Coupled scRNA-Seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in Cancer. Cell. 2020;182:872\u201385.e19.","journal-title":"Cell"},{"key":"8198_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/cac2.12386","volume":"43","author":"L Zhang","year":"2023","unstructured":"Zhang L, Li Q, Yang J, Xu P, Xuan Z, Xu J, et al. Cytosolic TGM2 promotes malignant progression in gastric cancer by suppressing the TRIM21-mediated ubiquitination\/degradation of STAT1 in a GTP binding-dependent modality. Cancer Commun (Lond). 2023;43:123\u201349.","journal-title":"Cancer Commun (Lond)"},{"key":"8198_CR26","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1053\/j.gastro.2023.02.005","volume":"164","author":"C Zhou","year":"2023","unstructured":"Zhou C, Weng J, Liu C, Liu S, Hu Z, Xie X, et al. Disruption of SLFN11 Deficiency-Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti-PD-1 Therapy efficacy in hepatocellular carcinoma. Gastroenterology. 2023;164:1261\u201378.","journal-title":"Gastroenterology"},{"key":"8198_CR27","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cellsig.2006.09.003","volume":"19","author":"HS Kim","year":"2007","unstructured":"Kim HS, Lee MS. STAT1 as a key modulator of cell death. Cell Signal. 2007;19:454\u201365.","journal-title":"Cell Signal"},{"key":"8198_CR28","doi-asserted-by":"crossref","unstructured":"Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202-9.","DOI":"10.1038\/nature13480"},{"key":"8198_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"8198_CR30","doi-asserted-by":"publisher","first-page":"5239","DOI":"10.1007\/s12035-021-02477-9","volume":"58","author":"B Kulkarni","year":"2021","unstructured":"Kulkarni B, Kumar D, Cruz-Martins N, Sellamuthu S. Role of TREM2 in Alzheimer\u2019s disease: a long road ahead. Mol Neurobiol. 2021;58:5239\u201352.","journal-title":"Mol Neurobiol"},{"key":"8198_CR31","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41590-023-01475-4","volume":"24","author":"MD Park","year":"2023","unstructured":"Park MD, Reyes-Torres I, LeBerichel J, Hamon P, LaMarche NM, Hegde S, et al. TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer. Nat Immunol. 2023;24:792\u2013801.","journal-title":"Nat Immunol"},{"key":"8198_CR32","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","volume":"182","author":"M Molgora","year":"2020","unstructured":"Molgora M, Esaulova E, Vermi W, Hou J, Chen Y, Luo J, et al. TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy. Cell. 2020;182:886\u2013900.e17.","journal-title":"Cell"},{"key":"8198_CR33","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1053\/j.gastro.2025.01.244","volume":"168","author":"D Yang","year":"2025","unstructured":"Yang D, Sun X, Wang H, Wistuba II, Wang H, Maitra A, et al. TREM2 depletion in pancreatic cancer elicits pathogenic inflammation and accelerates tumor progression via enriching IL-1\u03b2(+) Macrophages. Gastroenterology. 2025;168:1153\u201369.","journal-title":"Gastroenterology"},{"key":"8198_CR34","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jhep.2024.12.016","volume":"82","author":"S Cappuyns","year":"2025","unstructured":"Cappuyns S, Piqu\u00e9-Gili M, Esteban-Fabr\u00f3 R, Philips G, Balaseviciute U, Pinyol R, et al. Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma. J Hepatol. 2025;82:1036\u201349.","journal-title":"J Hepatol"},{"key":"8198_CR35","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.ccell.2024.05.001","volume":"42","author":"J Zhong","year":"2024","unstructured":"Zhong J, Xing X, Gao Y, Pei L, Lu C, Sun H, et al. Distinct roles of TREM2 in central nervous system cancers and peripheral cancers. Cancer Cell. 2024;42:968\u201384.e9.","journal-title":"Cancer Cell"},{"key":"8198_CR36","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.immuni.2014.01.006","volume":"40","author":"J Xue","year":"2014","unstructured":"Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity. 2014;40:274\u201388.","journal-title":"Immunity"},{"key":"8198_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00888-2","volume":"20","author":"X Chen","year":"2022","unstructured":"Chen X, Yang M, Yin J, Li P, Zeng S, Zheng G, et al. Tumor-associated macrophages promote epithelial-mesenchymal transition and the cancer stem cell properties in triple-negative breast cancer through CCL2\/AKT\/\u03b2-catenin signaling. Cell Commun Signal. 2022;20:92.","journal-title":"Cell Commun Signal"},{"key":"8198_CR38","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.1074\/jbc.273.8.4289","volume":"273","author":"W Gong","year":"1998","unstructured":"Gong W, Howard OM, Turpin JA, Grimm MC, Ueda H, Gray PW, et al. Monocyte chemotactic protein-2 activates CCR5 and blocks CD4\/CCR5-mediated HIV-1 entry\/replication. J Biol Chem. 1998;273:4289\u201392.","journal-title":"J Biol Chem"},{"key":"8198_CR39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12865-017-0237-5","volume":"18","author":"B Ge","year":"2017","unstructured":"Ge B, Li J, Wei Z, Sun T, Song Y, Khan NU. Functional expression of CCL8 and its interaction with chemokine receptor CCR3. BMC Immunol. 2017;18:54.","journal-title":"BMC Immunol"},{"key":"8198_CR40","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41374-019-0345-3","volume":"100","author":"X Zhang","year":"2020","unstructured":"Zhang X, Chen L, Dang WQ, Cao MF, Xiao JF, Lv SQ, et al. CCL8 secreted by tumor-associated macrophages promotes invasion and stemness of glioblastoma cells via ERK1\/2 signaling. Lab Invest. 2020;100:619\u201329.","journal-title":"Lab Invest"},{"key":"8198_CR41","doi-asserted-by":"crossref","unstructured":"Zhou H, Yao J, Zhong Z, Wei H, He Y, Li W, et al. Lactate-Induced CCL8 in tumor-associated macrophages accelerates the progression of colorectal cancer through the CCL8\/CCR5\/mTORC1 Axis. Cancers. 2023;15.","DOI":"10.3390\/cancers15245795"},{"key":"8198_CR42","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1073\/pnas.0712278105","volume":"105","author":"DY Lin","year":"2008","unstructured":"Lin DY, Tanaka Y, Iwasaki M, Gittis AG, Su HP, Mikami B, et al. The PD-1\/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc Natl Acad Sci USA. 2008;105:3011\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8198_CR43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","volume":"27","author":"MJ Butte","year":"2007","unstructured":"Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27:111\u201322.","journal-title":"Immunity"},{"key":"8198_CR44","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365\u20139.","journal-title":"Nat Med"},{"key":"8198_CR45","doi-asserted-by":"publisher","first-page":"5380","DOI":"10.1172\/JCI137110","volume":"130","author":"E Loeuillard","year":"2020","unstructured":"Loeuillard E, Yang J, Buckarma E, Wang J, Liu Y, Conboy C, et al. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J Clin Invest. 2020;130:5380\u201396.","journal-title":"J Clin Invest"},{"key":"8198_CR46","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909\u201320.","journal-title":"Lancet"},{"key":"8198_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101377","volume":"5","author":"J Sprooten","year":"2024","unstructured":"Sprooten J, Vanmeerbeek I, Datsi A, Govaerts J, Naulaerts S, Laureano RS, et al. Lymph node and tumor-associated PD-L1(+) macrophages antagonize dendritic cell vaccines by suppressing CD8(+) T cells. Cell Rep Med. 2024;5:101377.","journal-title":"Cell Rep Med"},{"key":"8198_CR48","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41392-021-00784-0","volume":"6","author":"J Chen","year":"2021","unstructured":"Chen J, Lin Z, Liu L, Zhang R, Geng Y, Fan M, et al. GOLM1 exacerbates CD8(+) T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages. Signal Transduct Target Ther. 2021;6:397.","journal-title":"Signal Transduct Target Ther"},{"key":"8198_CR49","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1136\/gutjnl-2019-318419","volume":"68","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, Hsu JL, et al. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut. 2019;68:1653\u201366.","journal-title":"Gut"},{"key":"8198_CR50","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1053\/j.gastro.2024.02.025","volume":"167","author":"J Chen","year":"2024","unstructured":"Chen J, Feng W, Sun M, Huang W, Wang G, Chen X, et al. TGF-\u03b21-Induced SOX18 elevation promotes hepatocellular carcinoma progression and metastasis through transcriptionally upregulating PD-L1 and CXCL12. Gastroenterology. 2024;167:264\u201380.","journal-title":"Gastroenterology"},{"key":"8198_CR51","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","volume":"177","author":"M Poggio","year":"2019","unstructured":"Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, et al. Suppression of Exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019;177:414\u201327.e13.","journal-title":"Cell"},{"key":"8198_CR52","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jhep.2012.01.029","volume":"57","author":"B Gao","year":"2012","unstructured":"Gao B, Wang H, Lafdil F, Feng D. STAT proteins - key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver. J Hepatol. 2012;57:430\u201341.","journal-title":"J Hepatol"},{"key":"8198_CR53","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.cmet.2020.10.021","volume":"33","author":"H Lv","year":"2021","unstructured":"Lv H, Lv G, Chen C, Zong Q, Jiang G, Ye D, et al. NAD(+) Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion. Cell Metab. 2021;33:110\u201327.e5.","journal-title":"Cell Metab"},{"key":"8198_CR54","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13046-020-01687-8","volume":"39","author":"H Zhang","year":"2020","unstructured":"Zhang H, Zhu C, He Z, Chen S, Li L, Sun C. LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p\/STAT1\/PD-L1 axis. J Exp Clin Cancer Res. 2020;39:179.","journal-title":"J Exp Clin Cancer Res"},{"key":"8198_CR55","doi-asserted-by":"crossref","unstructured":"Lv T, Xiong X, Yan W, Liu M, Xu H, He Q. Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression. J Immunother Cancer. 2022;10.","DOI":"10.1136\/jitc-2022-004763"},{"key":"8198_CR56","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.ccell.2023.02.005","volume":"41","author":"JD Klement","year":"2023","unstructured":"Klement JD, Redd PS, Lu C, Merting AD, Poschel DB, Yang D, et al. Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment. Cancer Cell. 2023;41:620\u201336.e9.","journal-title":"Cancer Cell"},{"key":"8198_CR57","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.cell.2020.05.003","volume":"181","author":"A Deczkowska","year":"2020","unstructured":"Deczkowska A, Weiner A, Amit I. The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway. Cell. 2020;181:1207\u201317.","journal-title":"Cell"},{"key":"8198_CR58","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1182\/blood-2012-09-457887","volume":"121","author":"T Oellerich","year":"2013","unstructured":"Oellerich T, Oellerich MF, Engelke M, M\u00fcnch S, Mohr S, Nimz M, et al. 2 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk\/STAT signaling axis. Blood. 2013;121:3889\u201399, s1-66.","journal-title":"Blood"},{"key":"8198_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06358-y","volume":"14","author":"S Chen","year":"2023","unstructured":"Chen S, Zhou B, Huang W, Li Q, Yu Y, Kuang X, et al. The deubiquitinating enzyme USP44 suppresses hepatocellular carcinoma progression by inhibiting Hedgehog signaling and PDL1 expression. Cell Death Dis. 2023;14:830.","journal-title":"Cell Death Dis"},{"key":"8198_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.472","volume":"5","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Wang X, Liu Y, Wu H, Zhu X, Ye C, et al. Phospholysine phosphohistidine inorganic pyrophosphate phosphatase suppresses insulin-like growth factor 1 receptor expression to inhibit cell adhesion and proliferation in gastric cancer. MedComm (2020). 2024;5:e472.","journal-title":"MedComm (2020)"},{"key":"8198_CR61","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jhep.2024.02.009","volume":"81","author":"P Xie","year":"2024","unstructured":"Xie P, Yu M, Zhang B, Yu Q, Zhao Y, Wu M, et al. CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma. J Hepatol. 2024;81:93\u2013107.","journal-title":"J Hepatol"},{"key":"8198_CR62","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1158\/0008-5472.CAN-24-0954","volume":"85","author":"P Xie","year":"2025","unstructured":"Xie P, Guo L, Yu Q, Zhao Y, Yu M, Wang H, et al. ACE2 Enhances Sensitivity to PD-L1 Blockade by Inhibiting Macrophage-Induced Immunosuppression and Angiogenesis. Cancer Res. 2025;85:299\u2013313.","journal-title":"Cancer Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08198-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08198-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08198-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T17:02:49Z","timestamp":1763485369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08198-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8198"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08198-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"845"}}